<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769013</url>
  </required_header>
  <id_info>
    <org_study_id>Transmal study version 2.0</org_study_id>
    <nct_id>NCT02769013</nct_id>
  </id_info>
  <brief_title>Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity</brief_title>
  <acronym>TRANSMAL</acronym>
  <official_title>Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the effect of neglected tropical diseases on Plasmodium falciparum transmission in
      an area of co endemicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project is divided in three different work packages that cover the life cycle of P.
      falciparum :

        1. In Work Package 1 (WP1) the investigators will assess whether S. haematobium infection
           increases the human reservoir of P. falciparum by increasing the carriage rate and
           incidence of P. falciparum gametocytaemia as well as by increasing the proportion and
           incidence of subject with sub-microscopic P. falciparum infection. The investigators
           will also determine whether this increase in gametocyte carriage is a consequence of an
           impairment of the immune response of helminth infected subjects to P. falciparum.

        2. In Work Package 2 (WP2) the investigators will determine whether the transmission of the
           sexual forms of P. falciparum from the human host to mosquito is increased in S.
           haematobium infected subjects compared to uninfected controls. Moreover the
           investigators will study whether the immunological changes induced in S. haematobium
           infected subjects lead to a decrease of the transmission reducing activity of IgG
           specific to Pfs48/45 and Pfs230 (both capable of blocking/impairing further development
           of P. falciparum in the mosquito gut).

        3. Finally in Work Package 3 (WP3) the investigators will assess whether S. haematobium
           infection affects the transmission of P. falciparum from the mosquito to the human host.
           This effect will be determined indirectly by assessing whether S. haematobium infected
           subjects are more attractive to mosquitoes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Plasmodium falciparum gametocytes and/or asexual blood stages</measure>
    <time_frame>15 months</time_frame>
    <description>Presence of Plasmodium falciparum gametocytes and/or asexual blood stages will be assessed by a quantitative real-time PCR assay in the blood obtained from participants. Unit of measurements for both parameters is numbers/µl.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive serum antibodies specific to the asexual and gametocyte stages of Plasmodium falciparum.</measure>
    <time_frame>15 months</time_frame>
    <description>Number of participants with serum antibodies against P. falciparum gametocyte and/or asexual blood stage antigens will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of mosquitoes attracted to Schistosoma-infected participants to non-infected individuals in a wind-tunnel assay.</measure>
    <time_frame>15 months</time_frame>
    <description>100 mosquitoes will be released to Schistosoma infected and non-infected participants simultaneously lying in different tents in a two-way olfactometer.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Plasmodium infected Anopheles mosquitoes per individual per night</measure>
    <time_frame>3 months</time_frame>
    <description>Mosquitoes will be collected by Human Landing catches and species of mosquitoes and presence of Plasmodium falciparum will be determined by morphology and PCR.</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">395</enrollment>
  <condition>Malaria Transmission</condition>
  <arm_group>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <description>Asymptomatic volunteers infected with S. haematobium and living in Gabon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S. haematobium negatives in Gabon</arm_group_label>
    <description>Volunteers not infected with S. haematobium and living in Gabon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
    <description>Asymptomatic volunteers infected with S. haematobium and living in Ghana</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S. haematobium negatives in Ghana</arm_group_label>
    <description>Volunteers not infected with S. haematobium and living in Ghana</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-treatment follow up</intervention_name>
    <description>No active intervention; medical support provided if needed</description>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium negatives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
    <arm_group_label>S. haematobium negatives in Ghana</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>S. haematobium treatment</intervention_name>
    <description>Praziquantel-treatment for S. haematobium positive volunteers</description>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
    <other_name>Praziquantel-treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Post treatment follow up</intervention_name>
    <description>No active intervention; medical support provided if needed.</description>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium negatives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
    <arm_group_label>S. haematobium negatives in Ghana</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olfactometer experiment</intervention_name>
    <description>No active intervention; medical support provided if needed.</description>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium negatives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
    <arm_group_label>S. haematobium negatives in Ghana</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample and urine collection potentially containing genetic material of Plasmodium
      falciparum and Schistosoma haematobium
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population are subjects aged from 6 to 30 years since both adults and children
        have been shown to be a reservoir of P. falciparum. Participants will be recruited in two
        African villages located in Gabon (lambarene) and Ghana Asokwa submetropolitan area in
        Kumasi, Ghana. Settings in the two locations are different and represent a rural area with
        very high infectious pressure from helminths infection (S. haematobium and geohelminths) as
        well as year-round transmission of malaria in the Central African rain forest (Lambaréné)
        and a more densely populated area in West Africa with pronounced seasonal variation in
        malaria transmission and high endemicity of S. haematobium but very little other
        helminthiases due to well-implemented mass treatment campaigns.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged from 6 to 30 years

          -  Without severe or moderate disease

          -  Agreement to be enrolled in the study (written informed consent or consent by the
             legal representative and assent)

          -  Living in the study area for at least 1 year

        Exclusion Criteria:

          -  Anaemia with haemoglobin less than 8g/dl

          -  Know sickle cell disease

          -  Macroscopic haematuria

          -  Any other know severe disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulysse ATEBA NGOA, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CERMEL, Lambarene, GABON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oumou MAIGA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KCCR, Kumasi, Ghana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin MORDMÜLLER, PD.Dr</last_name>
    <phone>0049707129</phone>
    <phone_ext>85446</phone_ext>
    <email>benjamin.mordmueller@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayôla Akim ADEGNIKA, Dr</last_name>
    <phone>0024107989191</phone>
    <email>aadegnika@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ayôla Akim ADEGNIKA</name>
      <address>
        <city>Lambarene</city>
        <state>Albert Schweitzer Hospital</state>
        <zip>118</zip>
        <country>Gabon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayôla Akim ADEGNIKA, Dr</last_name>
      <phone>0024107989191</phone>
      <email>aadegnika@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ulysse ATEBA NGOA, Dr</last_name>
      <phone>0024107989191</phone>
      <email>ulyssus7000@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ulysse ATEBE NGOA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald EDOA, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Claude DEJON, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KCCR</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ellis OWUSU-DABO, Dr</last_name>
      <phone>002333220</phone>
      <phone_ext>60451</phone_ext>
      <email>owusudabo@kccr.de</email>
    </contact>
    <contact_backup>
      <last_name>Oumou MAIGA, PhD</last_name>
      <phone>002333220</phone>
      <phone_ext>60451</phone_ext>
      <email>maiga@bni-hamburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Oumou MAIGA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Gabon</country>
    <country>Ghana</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schistosoma haematobium plasmodium falciparum transmission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

